Printer Friendly

NEW DRUG FOR ANGINA GAINS MARKET CLEARANCE

 NEW DRUG FOR ANGINA GAINS MARKET CLEARANCE
 PHILADELPHIA, Jan. 2 /PRNewswire/ -- The first new nitrate compound


for the prevention of angina in 30 years has been cleared for marketing, Wyeth-Ayerst Laboratories, a division of American Home Products Corporation (NYSE: AHP), announced today. The product will be launched under the trademark Ismo(R) (isosorbide mononitrate).
 Ismo, when used according to its unique dosing schedule, has been shown to avoid the tolerance (gradual loss of efficacy) that has been attributed to older nitrates in both the oral and patch formulations. This avoidance of tolerance was demonstrated in a unique clinical trial conducted by Wyeth-Ayerst Laboratories as part of its clinical development of the product.
 An additional feature that differentiates Ismo from other nitrates is that dosage adjustments are not required for elderly patients or in patients with various degrees of renal, hepatic, or cardiac dysfunctions. Ismo, unlike other oral nitrate tablets, is nearly 100 percent bioavailable.
 Side effects seen with Ismo were similar to those seen with other nitrates. The most common were headache, dizziness and nausea.
 Ismo is currently a leading form of angina therapy in Europe where it has been developed by Boehringer Mannheim GmbH. Boehringer Mannheim's U.S. pharmaceutical affiliate, Boehringer Mannheim Pharmaceuticals Corporation (BMPC), will participate in the promotion of the product in the United States.
 It is anticipated that Ismo, which will be available in pharmacies in mid-March, will be priced competitively with existing long-acting nitrate formulations.
 Wyeth-Ayerst Laboratories, a division of American Home Products Corporation, is a major research-oriented pharmaceutical company with leading products in the areas of female health care, cardiovascular and metabolic disease therapies, CNS, anti-inflammatory agents, vaccines, and infant nutritionals. American Home Products Corporation is a worldwide manufacturer and marketer of prescription drugs, medical supplies and diagnostic equipment, over-the-counter medicines, and food products.
 With the clearance of Ismo, Boehringer Mannheim Pharmaceuticals Corporation begins commercial operations in the United States as a developer and marketer of important new therapies for cardiovascular, metabolic, and oncologic diseases. BMPC is part of Boehringer-Mannheim America, which specializes in diagnostics, orthopedics, pharmaceuticals and biochemicals.
 -0- 1/2/92
 /CONTACT: Audrey Ashby of Wyeth-Ayerst Laboratories, 215-971-5823, or Shellie Winkler of Lobsenz-Stevens, 212-684-6300, for Wyeth-Ayerst Laboratories/
 (AHP) CO: Wyeth-Ayerst Laboratories; American Home Products Corporation ST: Pennsylvania IN: MTC SU: FC-CK -- NY055 -- 6223 01/02/92 14:53 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 2, 1992
Words:387
Previous Article:SCORPIONS HIGHLIGHT MORGAN CREEK SOUNDTRACK FOR 'FREEJACK' ROCK'N'ROLL, ALTERNATIVE, METAL, GRUNGE!
Next Article:CLEVELAND CLINIC FLORIDA ACCEPTING MEDICARE ASSIGNMENT
Topics:


Related Articles
ASTRA TO MARKET NEW HEART DRUG
MARION MERRELL DOW RECEIVES CLEARANCE TO MARKET ONCE-DAILY CARDIZEM CD FOR ANGINA
MARION MERRELL DOW REPORTS 16 PERCENT GAIN IN THIRD-QUARTER EARNINGS PER SHARE
NEW ONCE-A-DAY DRUG FOR ANGINA GAINS U.S. MARKET CLEARANCE
ASTRA NASAL ALLERGY DRUG RECEIVES U.S. MARKETING CLEARANCE
SANDOZ AND MARION MERRELL DOW ANNOUNCE CO-PROMOTION ARRANGEMENT
FDA APPROVES DILACOR XR(R) (DILTIAZEM HCL) FOR TREATMENT OF ANGINA; DILACOR XR ONE OF MOST AFFORDABLE CALCIUM CHANNEL BLOCKERS IN U.S.
RPR Seeks FDA Clearance For Drug To Treat Unstable Angina
RPR Submits Applications in 16 European Countries For Drug to Treat Unstable Angina
EECP(R) Proven Safe and Effective First-Choice Intervention for Treatment of Chronic Stable Angina

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters